FDA Approves Welireg + Lenvima for Advanced Kidney Cancer After Immunotherapy — PFS Win, No Overall-Survival Benefit
September 24, 2026. The FDA approved Welireg (belzutifan, Merck) in combination with Lenvima (lenvatinib, Eisai) for adults with advanced renal cell carcinoma (RCC) with a clear cell component "following treatment with a PD-1 or PD-L1 inhibitor" — including patients who progressed during/after therapy or within six months of completing adjuvant PD-1 treatment (CURE, citing the FDA announcement).
The approval is based on the Phase 3 LITESPARK-011 trial (NCT04586231), which randomized 747 patients to belzutifan/lenvatinib or cabozantinib (Cabometyx)1:
- Median PFS: 14.6 months vs 10.6 months favoring the combination — a 26% reduction in the risk of progression or death
- Objective response rate: 53% vs 40% — "indicating increased tumor shrinkage despite no statistically significant overall survival difference at final analysis23" (CURE key takeaways)
- Overall survival was NOT statistically significant: median OS 33.7 months (combination) vs 28.6 months (cabozantinib) at the final analysis
Recommended dosing: belzutifan 120 mg plus lenvatinib 20 mg, both once daily, until progression or unacceptable toxicity. Safety burden is real: Welireg carries a boxed warning for embryo-fetal toxicity plus anemia/hypoxia warnings, and adding lenvatinib introduces "cardiovascular risk and broad VEGFR-TKI toxicities including hypertension, thromboembolism, and organ dysfunction."
Why it matters: this gives post-immunotherapy advanced clear-cell RCC patients a second-line option built on an HIF-2α inhibitor plus a VEGFR-TKI rather than another TKI alone — with longer time to progression and deeper responses than cabozantinib, but no demonstrated survival advantage and a heavier toxicity stack.
-
An instance of Displacing an entrenched blockbuster drug requires defeating it in a direct, head-to-head trial. — The post-immunotherapy kidney-cancer slot was taken by beating the entrenched standard head-to-head on progression-free survival. ↩︎
-
An instance of Unprecedented surrogate biomarkers are replacing clinical outcomes to secure accelerated drug approvals. — Full approval rests on PFS and response-rate surrogates even though overall survival never statistically separates, confirming that surrogate endpoints now substitute for the survival outcome at the approval gate. ↩︎
-
An instance of PFS-driven accelerated approvals fail to guarantee durable overall survival benefits. — Market access granted on progression-free benefit even though final overall survival showed no significant advantage extends the PFS-without-OS pattern. ↩︎